IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, February 2023
Impact Factor: 7.301

Review on Good Distribution Practices

Salgar J. B., Bais S. K., Manisha Subhash Pawar
Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India

Abstract: *A thorough grasp of its administration is required in order to handle the distribution of medicines appropriately. The supply chain for pharmaceutical products has difficulties because of their predetermined shelf life and predetermined storage conditions. Regulating drug quality throughout distribution Is a crucial process. Medicines come in a variety of dose forms, such as pills, syrups, injectables, etc. Each of them must be kept under various environmental conditions based on the stability of Drug supplies. As a result of the potential for problems during the cold chain, cold chain products require additional care testing Self-inspections should be carried out to track the application and adherence to this GDP standard and to make any necessary recommendations. Correctional and preventative actions According to the USP, a pharmaceutical product's stability is defined as the "extent to which a product preserves, within prescribed limits, and The same qualities and traits that it has during its time in storage and use, or its shelf life possessed when it was being made. The documentation system should comprise data, procedures, instructions, protocols, contracts, records, certificates of analysis, and product specifications (relevant primarily to importers). These records should be accessible for auditing purposes and upon request from Licencing authorities. The documentation system should comprise data, procedures, instructions, protocols, contracts, records, certificates of analysis, and product specifications (relevant primarily to importers). These records ought to be accessible for audit and at the licencing authority's request. chain management and planning to ensure availability in retail stores while reducing the amount of product waste at various supply chain stages In comparison to chain management and planning, a large level of control is exercised during the distribution of medicines at the UK, USA, and Europe to ensure availability in retail stores without increasing the amount of wasted goods throughout the various supply chain phases. When compared to the US, UK, and Europe, a sizable level of control is exercised throughout the delivery of medications..*

Keywords: Good Distribution Practices by GMP.

I. INTRODUCTION

Good Distribution Practices (GDP) are a component of quality assurance that guarantee that items are consistently kept, transported, and handled under acceptable situation as required by the product specification or marketing authorization . Drug distribution quality control is a laborious process. Due to its set shelf life and storage conditions, the pharmaceutical products force chain faces obstacles. Since the numerous dosage forms (such as pills, syrups, injectable, etc.) must be transported and stored under diverse environmental conditions, A general rule cannot be used to handle medications. Regarding the need to handle Injectable, syrups, and pills shall widely vary. Range of cold chain products. Drugs are kept in storage between 2 and 8 degrees Celsius. Due to the possibility of product failure, care must be taken with cold chain products. During guest quality control testing. The efficiency and quality of performance.

In order to reduce environmental damage, the entire force chain is crucial. Therefore, producing only the quantities that are needed can greatly reduce the waste produced by the perishable supply chain.

Principle

In accordance with the Medicines and Cosmetics Act of 1940 and the Medicines and Cosmetic Rule of 1945, Rule 65 outlines the requirements to sell, store, exhibit, or distribute the medication.

All parties involved in the distribution of pharmaceutical items will be accountable. To ensure the integrity of the distribution network and the quality of pharmaceutical products are kept up during the distribution procedure. The distance from the manufacturer to The Reality in charge of providing or assigning. The product to Case or their representative.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, February 2023
Impact Factor: 7.301

The principles of GDP shall apply to pharmaceutical products throughout the distribution chain from the manufacturer to the entity in charge of allocating or providing pharmaceutical products for the case as well as to products that are moving backwards in the chain due to returns or recalls as a result. They shall also apply to pharmaceutical products that have been donated.

To ensure the quality and safety of pharmaceutical products, cooperation between all parties—including the government, customs agencies, law enforcement agencies, non supervising authorities, manufacturers, distributors, and realities liable for cases—is required. Pharmaceutical products assist in circumstances of exposure to fake pharmaceutical items.

The term "good distribution practise" (GDP) refers to the minimal standards that a non commercial Distributor must adhere to in order to guarantee the maintenance of drug quality and integrity throughout the supply chain.

In order to maintain the high quality and safety of pharmaceutical products, the World Health Organization has approved criteria for distribution that are referred to as Good Distribution Practices, or GDP.

According to the GDP standards, there are nine major principles that are briefly stated.

The distribution of pharmaceutical products must be regulated by national law in accordance with GDP criteria. (Specific item we discussed.)

The distributor, who will be in charge of ensuring the secure delivery of the pharmaceuticals or medical devices, should be a registered and legitimate organisation. It should only be possible for authorised individuals or businesses toThe import or export of pharmaceuticals. Only nations are eligible for distributors to carry out pharmaceutical product distribution. Where the item is legal.

Only businesses that are authorised to produce or interact with the pharmaceutical product may receive the services of a distributor.

The only third parties to whom duties and responsibilities may be delegated are those who also hold an the proper licence. Pharmaceutical medicines should only be provided by distributors or their agents to individuals or Entities that are qualified to buy such things themselves.

The subcontractor or company must be suitably qualified to do the activity. Authorised Pharmaceutical products should only be sold online to registered users. Authorized online drugstores or other recognised organisations.

1. 1.Allployees who are involved in distribution activities must be trained and qualified in accordance with GDP, as appropriate. Training must follow stated standards. Operating methods (SOPs). The workforce must receive basic and ongoing training. Related to their responsibilities, and be evaluated in line with a defined plan training regimen.

   Additionally, product handling, security, and safety considerations, as well as components of product identification, shall be covered in the personnel's training.

   The identification of fake pharmaceutical products and the prevention of fake Entering the supply chain with a pharmaceutical product. A log of every training session, which Information on the topics covered and the people trained, and it must be retained.
2. Important players in the pharmaceutical product distribution chain shall possess the skills and experience necessary to guarantee that pharmaceutical items are handled, delivered, and kept in accordance with their needs.
3. Adequate numbers of knowledgeable individuals must be involved in all phases of Ensuring the quality of the pharmaceutical items distributed to ensure product is kept up.
4. Employees who are involved in the distribution of pharmaceutical products must wear appropriate clothing and take other safety precautions for their own protection. The personnel shall receive protective gear as needed. Dealing with potentially dangerous pharmaceutical drugs, such as those that contain materials that are extremely active, poisonous, contagious, or sensitising.
5. Personnel hygiene procedures that are pertinent to the tasks to be performed must be established and followed. These processes must address personnel's health, hygiene, and attire.
6. Guidelines for employees' employment, such as the Contract and Temporary employees and others with access to pharmaceutical products must follow these rules. Created and implemented to help reduce the likelihood of such items Getting into the hands of unauthorised people or organisations.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, February 2023
Impact Factor: 7.301

II. DOCUMENTATION

1. The documentation system should contain the product specifications (applicable primarily to importers), procedures, instructions, Protocols, contract, Data, records, and Certificates of Analysis, whether they are in paper or digital form. These Documents must be accessible for audit and upon request from the licencing authority.
2. There should be written procedures available to describe the various Operations that could have an impact on the quality of the products or of the Distribution activities, including personnel training, receipt and inspection of incoming products, storage, deliveries, cleaning, and Premises upkeep, pest control, storage tracking and recordkeeping, and pest inspection Conditions, on-site stock security, stock removal of sellable items, returned goods, Complaints, recalls, audits, self-inspections, and assessments of contract acceptors, among other things. The related records of the actions conducted or the conclusions drawn should be kept.
3. Each document's title, type, and purpose should be stated in clear terms. The effective Date should be specified, and documents should be individually identified. Documents' contents should be explicit and clear. All paperwork should be accepted, Signed, dated, and should not be altered by the relevant authorised person(s).Without the required permission.
4. Documents should be regularly reviewed and kept current. Whenever a document A method should be in place to prevent unintentional use of the version that has been updated.
5. Records should be created or finished at the moment each action is taken in a fashion that makes it possible to trace all relevant activities or events. Data entry completed by hand should be crisp, readable, and permanent. Any changes to the entry should be Dated and Signed, and the Modification should Allow Reading of Original Information
6. A record of the products' receipt and distribution, noting the product, shall be kept. Name, transaction date, invoice/delivery order number, and the name and address of the buyer or supplier, the batch number, the expiration date, the quantity received or sold, and the stock Balance. Documents pertinent to the distribution (including records for samples)Should be kept up.
7. Documents should be stored for a period of time that complies with legal requirements and be accessible for retrieval
8. All ready documentation for the position should be available to each employee at all times. Tasks completed.
9. An electronic data processing system may record data, but detailed The procedures for the system in use should be accessible, and the precision of the Records ought to be examined. Entry and modification should only be permitted by authorised people. Data on the computer, and a history of additions and deletions should exist (audit).Access should be controlled by a password or some other method. The availability of the data, particularly audit trial data, is very crucial.

III. AREA AND TECHNOLOGY

1. 1.In order to maintain the required storage conditions, the premises should be designed or modified. Additionally, the premises should be sufficiently secured to Access that is not permitted and merchandise theft.
2. Receiving bays ought to shield goods from the elements. The area of reception Should be constructed and outfitted to permit the cleaning of arriving container Materials before storage, if necessary.
3. Storage spaces need to have enough space to accommodate the various product categories—those in quarantine as well as those that have been released, rejected, returned, or recalled—in an orderly and segregated manner.
4. These particular storage spaces ought to be the products in quarantine and those that are rejected, clearly designated products, Only authorised staff should be recalled or returned. Any system, such as(using a computerised and bar code method) Physical separation should result in Similar assurance of segregation and accessibility limitations.
5. The storage facilities need to have sufficient lighting and ventilation so that all tasks may be completed correctly and safely. Carefully maintain the property, making sure that repair and maintenance activities don't

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, February 2023
Impact Factor: 7.301

pose any risks.To the products' quality.

6. The property should be dry, spotless, and devoid of dust and accumulated waste. The writtenA cleaning procedure that specifies the frequency and techniques to be used should be avavailable.Usedep the space tidy. Cleaning should be done without exposing a source.
7. That Contamination. Maintaining cleaning records is a good idea. Infectious, cytotoxic,
   There should be suitable procedures for the use of sensitising agents like CTGTP.
   Mopping up any spills to guarantee that all contamination risks have been fully eliminated. Products should be kept off of the property space space Inspection.
8. Product storage conditions must follow the instructions listed on the product label. Every piece of equipment that affects product storage and distribution should be planned, placed, maintained, and cleaned to the appropriate standards. Purpose.
9. The storage spaces need to have recorders or other devices that will The storage conditions are continuously observed, and pertinent readings are recorded, including Extremes and minimums Daytime temperature and humidity. Appropriate measures for When the Storage conditions exist, the premises, equipment, and/or products should be taken. Are not met, and any subsequent actions should be documented.
10. Recorders and tools for keeping an eye on storage conditions When suitable, should be placed in regions where changes are most likely to occur and/or in the hottest and coldest places.
11. This measuring apparatus needs to be calibrated for the necessary Operating range at predetermined times. These measurement devices' calibration should.

IV. DELIVERY TO CUSTOMER RETURNS

Each incoming delivery should be examined for tampering and damage as soon as it is received. Physically comparing the incoming products' label descriptions, types, and quantities to the pertinent purchase order data is also recommended. If required, an Quarantined orpuaside for additional inspection, either the container or the entire delivery Investigation. A written procedure should specify the kind and scope of checks Adhere to written procedures when storing items that have special storage needs (such as drugs or cold-chain products). Before storing, any essential cleaning of incoming containers should be performed. Any work done on the incoming merchandise The products' quality shouldn't be affected. Labeling for products in cartons or bulk packs should include at least the Name of the product, batch number, and expiration or retest date.

1. Items with missing seals, damaged packaging, or possible Contamination or tampering cannot be sold or provided. Periodically balancing the stock Should be done by comparing the recorded and actual product quantities. All Substantial stock
2. Discrepancies should be looked into to rule out accidental errors and wrong Release of stock.
3. Discrepancies should be looked into to rule out accidental mistakes and incorrect stock issuance.
4. Products with an expiration date cannot be supplied or received after they've run out The products' expiration date or so close to it that it is likely to happen before the products Are utilised by the user.
5. A procedure should be in place to guarantee that goods that are about to expire are sold or Distributed initially (Earliest-Expiry-First-Out, EEFO). If there are no deadlines for FIFO (First-In First-Out) should be used while ordering the products. But variations could occur In extraordinary circumstances where such a divergence is appropriate and justifiable, be permitted.
6. Only authorised individuals or wholesale dealers shall receive deliveries. To provide the goods.
7. AAritten, appropriate, and justified delivery procedure.

V. SELF-INSPECTION

1. 1.Self inspections should be carried out to track the implementation of this GDP standard and compliance, and to suggest necessary Both corrective and proactive actions.
2. Self-inspections should be carried out in a thorough and objective manner. By trained, qualified staff. There ought to be a Written guidelines for self-inspection that list the participants Self-inspection, self-inspection frequency, and inspection

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, February 2023
Impact Factor: 7.301

3. All self-evaluations ought to be documented. Every observation made during the inspection should be included in this record. If irregularities or shortcomings are found, their source should be determined. Be committed to taking corrective and preventative measures (CAPA)Must be recorded and followed up on.

Transportation
Theory
The wholesaler distributor has the duty to ensure that the supply of Medicinal Products, the conditions of shipping are such that the product's quality is maintained, To provide proper security and to guard against theft, adulteration, and breakage Environmental standards are upheld while being transported. Adequate safety measures Should be interpreted in this way. The storage requirements should be followed when transporting pharmaceutical products. Pointed out.
Transportation
In accordance with the established parameters stated on the packaging information, the necessary storage conditions for pharmaceutical items should be maintained during transportation. Fine the event that a deviation occurs while being transported, it should be reported to the Receiver and distributor of the impacted pharmaceuticals.
When the recipient observes the deviation, they should inform the Distributor. When necessary, the pharmaceutical product's maker should Been in touch with to ask for advice on the best course of action.
The distributor is in charge of making certain that the tools and vehicles used to There are procedures in place for the upkeep and operation of all vehicles and equipment used in The cleaning and security procedures involved in distribution. Equipment for measuring temperature inside of moving vehicles and/or Containers,

VI. REPORTED PRODUCT ISSUES

1. A written procedure outlining the steps to be taken in handling all written and verbal complaints regarding a potential product defect should be in place. Every complaint regarding a specific product should have a record.
2. The process for dealing with product complaints must make sure that the issues raised are looked into, addressed, and that corrective measures are done to avoid reoccurring issues. Records should contain all initial information regarding the product complaint, investigations, and subsequent corrective and preventive actions, including product recalls.
3. A representative from the company will be assigned to deal with Product complaints. The distributor and recipient of the impacted pharmaceutical products must be able to start investigations.
4. If a product problem is found or suspected to exist in a batch, it should be investigated to see if any other batches are also impacted.
5. Reviewing product complaint data frequently to look for any indications ofDifficulties that are specific or persistent and need care.

6.1 Informational Provision

A component of quality assurance known as good distribution practise (GDP) makes sure that products are consistently kept, transported, and handled in a manner that is fit for their intended
use. Necessary to meet the product standards for making authorised (MA) products. Wholesalers that want to distribute or are currently distributing pharmaceutical products in a member State
Any public service obligation imposed on wholesalers operating on their territory will be disclosed to wholesalers by the components authorities of this and any other member states as necessary. Any public service obligation imposed on wholesalers operating on their territory will be disclosed to wholesalers by the components authorities of this and any other member states as necessary.

6.2 Recall of Products

1. There should be a written description of both a non-urgent product recall procedure and an emergency plan for urgent product recalls.
2. All product recalls should be coordinated and carried out by a specific person or group of people.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, February 2023
Impact Factor: 7.301

3. All customers to whom the product has been distributed must be notified as soon as possible in the event of a product recall. The recall statement should include if the recall should be implemented at there tail level, whether it is necessary to remove all recalled goods from the shelves right away, and whether it is necessary to prevent their mingling with other sellable goods.
4. 4 A product recalls should be reported to the local regulatory body. The overseas equivalents and/or Regulatory authorities must be notified of the recall if the product is exported. If a product recall affects a specific batch, this should also be taken into account.
5. 5.To ascertain if more batches are also Affected. The Product Recall Coordinator must approve all actions related to the product recall. Business, regulatory bodies, and Recorded. A final Report should be issued, detailing the recall process's progress. Includes the rapprochement between Delivered.

VII. RETURNED PRODUCTS

1. There should be a written procedure outlining how returned products should be handled and the records that go along with them. Products ought to be stored.
2. All returned goods should be stored separately from stock that can be sold to preventRedistributed until a decision regarding Their disposition has been made.

- Products that have been returned should only be put back into stock that can be sold.The following are verified:
- The goods are in their initial, untouched, secondary packing without any openings, andAre in good shape;It is known that the goods have been handled, stored, and transported in accordance withConditions;The shelf life that is still left is adequate;
- The products' remaining shelf life is satisfactory; d) they have been reviewed and evaluated by qualified and suitably suited individuals.
- The nature of the product and any unique storage requirements should be considered in this evaluation. Required, as well as how long it had been since it was distributed. Special It is important to pay attention to thermolabile goods. Advice from the marketing team should be sought. Holder of the necessary authorization (product licencing) or manufacturer Whenever there is any doubt Because of the product's quality, it shouldn't be deemed appropriate for return.

3. A designated, accountable person should formally release the returned goods to saleable Stock.

VIII. FRAUDULENT GOODS

The sale and distribution of an allegedly fraudulent good should be stopped right away. Any fake goods discovered in the supply chain should be Physical separation from other materials is necessary to prevent confusion.

They ought to be prominently marked with "Not for Sale" or other similar words or phrases. Records and documentation of all pertinent actions related to such products are required. Retained.

The marketing licence holder and the regulatory body It is important to notify the original product's authorization. Immediately.

After a product is confirmed to be a fake, a formal decision should be made to remove it from the market and make sure it doesn't re-enter the supply chain, including retention. Any samples required for legal, regulatory, or public health purposes and plans for disposing of it. All decisions in this regard should be adequate documentation

Principle of stability testing:

Stability

The USP describes a pharmaceutical product's stability as the "extent to which a Throughout its storage and use periods, the product retains, within the predetermined limitations. The same qualities and features that it had at the time of manufacture, i.e., its shelf life Its. production."Stability testing's goal is to demonstrate how an active's quality can be improved. A chemical or medicinal product changes over time while being influenced by a number of different Of ambient elements including heat, moisture, and light. Aside from that Stability is affected by elements specific to the product, such as its chemical and physical features. The dose form, its active ingredient, pharmaceutical excipients, and Composition, production method, and container closure system type.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, February 2023
Impact Factor: 7.301

Stability Testing Protocol:

A written document describing the essential elements of a regulated and controlled stability testing procedure is required before stability testing can begin. A well monitored stability study.

The sort of testing condition is depending on the compound's inherent stability, therefore The protocol is dependent on the dose form and suggested container closing technology. The kind of goods or drug substance.

Additionally, the approach may differ based on whether the medicine is brand-new or previously available in the Market. The protocol should also take into account the areas where the product is intended to bused. Be advertised, for instance, if the product is intended for use in climate zones I–III, Iva, and IVb, all of these zones must be included in the stability programme.

The importance of stability testing:

Other advantages of stability studies in the developmental stage or of the commercial products are to give a database that may be useful in choosing suitable Development of innovative formulations, excipients, and container closing mechanisms Product's shelf life and storage requirements for the creation of a new Creation of a registration document for the product, support for the claimed shelf life for To ensure that no changes have been made to the registration dossier and to Processes during formulation or manufacture that might be harmful to stability

Various stability testing methodologies

1. In-the-moment testing
2. expedited examinations
3. Testing in the middle Test
4. forced degradation.

IX. STAGES OF DRUGS AND PRODUCT DEVELOPMENT AND STABILITY TESTING

- Commercial manufacture
- Shipping and distribution
- Modifications after approval
- Market monitoring

X. DISCUSSION

Reviewing the available GDP literature around the world demonstrates that there is a growing understanding of GDP. Highest in the United States of America (USA), then in the United Kingdom, then Europe.

The use of vehicles in western nations that include climate control (sometimes referred to as Reefer containers) are required, although in Indian subcontinental nations neither Neither using such vehicles Temperature regulation in stores Counters are treated seriously. Minimization of drug waste, notably in Medications used orally have Become a priority in order to execute supply chain sustainability Chains.

The majority of the time, multidisciplinary teams from Inside the Network must conduct a centralised assessment of public health issues brought on by drug shortages. Participants in the Network, Usually call for the involvement of individuals or professionals connected to, but not While utilising the Network, Typically, effective risk management communications require swift and sophisticated communication. Measures that may be necessary. A programme that is tailored to the local environment. After the initial shock to the system, the repercussions of these crises may be more long-lasting.

Instance in Europe

A reflection paper on shortfalls in the supply of pharmaceutical products brought on by manufacturing and Good Manufacturing Practice was released by the European Medicines Agency (EMA).Issues with compliance. The topic of this reflection paper is public health emergencies. That result from unanticipated interruptions in the production process, such as Issues with manufacturing and GMP compliance that affect pharmaceutical products Human usage, regardless of their method of authorisation, when coordination is required Of the Community's assessment and risk-reduction measures has been determined. Although national governments continue to be in charge of controlling and regulating the domestic market, Member States may encounter challenges when pursuing exclusively national

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, February 2023
Impact Factor: 7.301

objectives whenA pan-European crisis while the distribution network was encountered. The system isMore and more people are coordinating with the European Medicines Agency (EMA).

Case study: India

The Central Drugs Standards Control Organization (CDSCO) of the Indian Government has released a consolidated paper on good distribution practises (GDP) for Pharmaceuticals to guarantee the authenticity and quality of pharmaceuticals Throughout every step of the distribution process including sourcing, purchase, and storage, Distribution, transportation, record-keeping, and documentation procedures. Here is Regarded as a historical advancement in boosting GDP during numerous procedures Relating to supply chain management.

XI. CONCLUSION

To ensure availability in medical retail stores without expanding the amount of inventory, efficient supply chain management and planning are required. Wasteful items at various stages of the supply chain. The cGMP is a flexible type ofA rule that provides the most recent information on "Dos and Don'ts." But the nowhere Emphasis has been placed on the concept of current GDP Good Distribution Practices practises. The pharmaceutical supply chain management must therefore make ongoing A systematised update to the distribution procedures.

REFERENCES

[1]. World Health Organization (WHO) Good Distribution Practices for Pharmaceutical Products. WHO Technical Report Series, No. 957, 2010.

[2]. Pharmaceutical-operation Scheme (PIC/S) Guide to Good Distribution Practice GDP) for Medicinal Products.

[3]. HAS Guidelines on Good Manufacturing Practice for Cell, Tissue And Gene Therapy Products

[4]. USP <1044> Cryopreservation of Cells .

[5]. Aihie Osarenkhoe (Year: 2007) (Department of Business Administration, University of Gävle, Gävle, Sweden), Az-Eddine Bennani(Reims Management School, Reims, France) Title: An exploratory study of implementation of customer relationship management strategy, Source: Emerald Group Publishing Limited Country: Sweden/France

[6]. Bas Hillebrand, Wim G. Biemans (Year : 2004) Title: Links between Internal and External Cooperation in Product Development: Exploratory Study, Source: Journal of Product Innovation Management Volume 21, Issue 2, pages 110–122, March 2004 Country: Netherlands

[7]. Chambliss WG, Carroll WA, Kennedy D, Levine D, Moné MA, Ried LD, Shepherd M, Yelvigi M.(Year:2012) Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, USA. wchambli@olemiss.edu Title: Role of the pharmacist in preventing distribution of counterfeit medications, Source: J Am Pharm Assoc (2003). 2012 Mar-Apr;52(2):195-9. doi: 10.1331/JAPhA.2012.11085 Country: USA

[8]. Draksiene G, Petkevicius H, Radziūnas R (Year : 2003) Title: Documentation of good distribution practice of medicines and its implementation in Lithuanian drug distribution companies, Source: Department of Drug Technology and Pharmaceutical Management, Kaunas University of Medicine, Kaunas, Lithuania. gailute.draksiene@mail.lt, Country: Lithuanian

[9]. Jackson G, Patel S, Khan S. (Year: 2011) Cardiac Department, St. Thomas Hospital, London, UK. gjcardiol@talk21.com\ Title: Assessing the problem of counterfeit medications in the United Kingdom, Source : © 2011 Blackwell Publishing Ltd., Country: UK